Ibrutinib Improves Outcomes for Patients With MCL in TRIANGLE Study

Martin Dreyling, MD, discusses the outcomes of the phase 3 TRIANGLE study evaluating ibrutinib in patients with mantle cell lymphoma.

Martin Dreyling, MD, Department of Internal Medicine III, LMU University Hospital Munich, in Germany, discusses the outcomes of the phase 3 TRIANGLE study (NCT02858258) evaluating ibrutinib (Imbruvica) in patients with mantle cell lymphoma (MCL).

At the 2022 ASH Annual Meeting, Dreyling presented that patients can see improvements with ibrutinib added to standard chemoimmunotherapy induction followed by autologous stem cell transplantation (ASCT) and 2 years of maintenance. The TRIANGLE study compared this combination with standard chemoimmunotherapy induction and ASCT alone for younger patients with MCL.

Dreyling notes that patients with MCL harboring p53 mutations are typically hard to treat. However, data from this trial shows the positive outcomes that come with the addition of ibrutinib.


Transcription:

0:08 | Overall survival is also improved by about 5%, which is quite encouraging for both ibrutinib-containing arms. Secondly, the kind of patients which are hard to treat, these are the ones with p53 mutations, they have an excellent outcome now with the addition of ibrutinib.

0:37 | To sum up, the lifecycle of autologous transplant in mantle cell lymphoma is over and I am quite confident that this treatment will be included in both the United States guidelines as well as the international ones.